share_log

Forte Biosciences Secures $53M In Oversubscribed Private Placement To Advance FB102 Clinical Programs Across Autoimmune Indications, With Key Data Readouts Expected In 2025

Benzinga ·  Nov 20, 2024 22:05
Forte Biosciences Secures $53M In Oversubscribed Private Placement To Advance FB102 Clinical Programs Across Autoimmune Indications, With Key Data Readouts Expected In 2025
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment